Literature DB >> 30668266

Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis.

John Mascarenhas1, Maria R Baer2, Craig Kessler3, Elizabeth Hexner4, Douglas Tremblay1, Leah Price5, Lonette Sandy1, Rona Weinberg6, Heike Pahl7, Lewis R Silverman1, Judith D Goldberg5, Heidi Kosiorek8, Amylou C Dueck8, Ronald Hoffman1.   

Abstract

Entities:  

Year:  2019        PMID: 30668266      PMCID: PMC6530779          DOI: 10.1080/10428194.2018.1532509

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  8 in total

1.  Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.

Authors:  Elizabeth O Hexner; John Mascarenhas; Josef Prchal; Gail J Roboz; Maria R Baer; Ellen K Ritchie; David Leibowitz; Erin P Demakos; Crystal Miller; James Siuty; Jill Kleczko; Leah Price; Grace Jeschke; Rona Weinberg; Titiksha Basu; Heike L Pahl; Attilio Orazi; Vesna Najfeld; Roberto Marchioli; Judith D Goldberg; Lewis R Silverman; Ronald Hoffman
Journal:  Leuk Lymphoma       Date:  2015-02-20

2.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

4.  Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET).

Authors:  Giovanni Barosi; Dominique Bordessoule; Jean Briere; Francisco Cervantes; Jean-Loup Demory; Brigitte Dupriez; Heinz Gisslinger; Martin Griesshammer; Hans Hasselbalch; Rajko Kusec; Marie-Caroline Le Bousse-Kerdiles; Nicola L Liberato; Monia Marchetti; John T Reilly; Jurgen Thiele
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

5.  The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.

Authors:  Ross L Levine; Marc Loriaux; Brian J P Huntly; Mignon L Loh; Miroslav Beran; Eric Stoffregen; Roland Berger; Jennifer J Clark; Stephanie G Willis; Kim T Nguyen; Nikki J Flores; Elihu Estey; Norbert Gattermann; Scott Armstrong; A Thomas Look; James D Griffin; Olivier A Bernard; Michael C Heinrich; D Gary Gilliland; Brian Druker; Michael W N Deininger
Journal:  Blood       Date:  2005-08-04       Impact factor: 22.113

6.  Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Authors:  Fabio P S Santos; Hagop M Kantarjian; Nitin Jain; Taghi Manshouri; Deborah A Thomas; Guillermo Garcia-Manero; Debra Kennedy; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

7.  Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.

Authors:  Elizabeth O Hexner; Cynthia Serdikoff; Mahfuza Jan; Cezary R Swider; Candy Robinson; Shi Yang; Thelma Angeles; Stephen G Emerson; Martin Carroll; Bruce Ruggeri; Pawel Dobrzanski
Journal:  Blood       Date:  2007-11-05       Impact factor: 22.113

Review 8.  A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis.

Authors:  John Mascarenhas; Ronald Hoffman
Journal:  Blood       Date:  2013-04-09       Impact factor: 22.113

  8 in total
  5 in total

Review 1.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Authors:  Lei Zhong; Yueshan Li; Liang Xiong; Wenjing Wang; Ming Wu; Ting Yuan; Wei Yang; Chenyu Tian; Zhuang Miao; Tianqi Wang; Shengyong Yang
Journal:  Signal Transduct Target Ther       Date:  2021-05-31

2.  Lestaurtinib potentiates TRAIL-induced apoptosis in glioma via CHOP-dependent DR5 induction.

Authors:  Yingxiao Cao; Shiqi Kong; Yuling Xin; Yan Meng; Shuling Shang; Yanhui Qi
Journal:  J Cell Mol Med       Date:  2020-05-22       Impact factor: 5.310

3.  High-throughput screening against protein:protein interaction interfaces reveals anti-cancer therapeutics as potent modulators of the voltage-gated Na+ channel complex.

Authors:  Paul A Wadsworth; Oluwarotimi Folorunso; Nghi Nguyen; Aditya K Singh; Daniela D'Amico; Reid T Powell; David Brunell; John Allen; Clifford Stephan; Fernanda Laezza
Journal:  Sci Rep       Date:  2019-11-15       Impact factor: 4.379

4.  Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.

Authors:  Léa Hoisnard; Bénédicte Lebrun-Vignes; Sébastien Maury; Matthieu Mahevas; Khalil El Karoui; Lydia Roy; Anissa Zarour; Marc Michel; José L Cohen; Aurélien Amiot; Pascal Claudepierre; Pierre Wolkenstein; Philippe Grimbert; Emilie Sbidian
Journal:  Sci Rep       Date:  2022-05-03       Impact factor: 4.379

5.  TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers.

Authors:  Angelina T Regua; Noah R Aguayo; Sara Abu Jalboush; Daniel L Doheny; Sara G Manore; Dongqin Zhu; Grace L Wong; Austin Arrigo; Calvin J Wagner; Yang Yu; Alexandra Thomas; Michael D Chan; Jimmy Ruiz; Guangxu Jin; Roy Strowd; Peiqing Sun; Jiayuh Lin; Hui-Wen Lo
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.